Overview

Study Evaluating the Efficacy and Safety of IPI 504 in Patients With Advanced Dedifferentiated Liposarcoma

Status:
Withdrawn
Trial end date:
2010-12-01
Target enrollment:
Participant gender:
Summary
The primary objective of the study is to determine the safety profile and overall response rate of IPI 504 in patients with advanced dedifferentiated liposarcoma.
Phase:
Phase 2
Details
Lead Sponsor:
Infinity Pharmaceuticals, Inc.